241 related articles for article (PubMed ID: 9691402)
1. High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.
Mauser-Bunschoten EP; Zaaijer HL; van Drimmelen AA; de Vries S; Roosendaal G; van den Berg HM; Lelie PN
Vox Sang; 1998; 74(4):225-7. PubMed ID: 9691402
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
3. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs.
Grosse-Bley A; Eis-Hübinger AM; Kaiser R; Oldenburg J; Brackmann HH; Schwarz TF; Schneweis KE
Thromb Haemost; 1994 Oct; 72(4):503-7. PubMed ID: 7878623
[TBL] [Abstract][Full Text] [Related]
4. [Prevalence of anti-human parvovirus B19 IgG antibody among blood donors in Jilin province].
Wei Q; Li Y; Wang JW; Wang H; Qu JG; Hung T
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):60-2. PubMed ID: 16816866
[TBL] [Abstract][Full Text] [Related]
5. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S
Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
[TBL] [Abstract][Full Text] [Related]
6. Parvovirus B19 may have a role in the pathogenesis of juvenile idiopathic arthritis.
Gonzalez B; Larrañaga C; León O; Díaz P; Miranda M; Barría M; Gaggero A
J Rheumatol; 2007 Jun; 34(6):1336-40. PubMed ID: 17477467
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of parvovirus B19 IgG in children affected by juvenile idiopathic arthritis.
Weissbrich B; Süss-Fröhlich Y; Girschick HJ
Arthritis Res Ther; 2007; 9(4):R82. PubMed ID: 17760961
[TBL] [Abstract][Full Text] [Related]
8. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation.
Soucie JM; Siwak EB; Hooper WC; Evatt BL; Hollinger FB;
Transfusion; 2004 Aug; 44(8):1179-85. PubMed ID: 15265122
[TBL] [Abstract][Full Text] [Related]
9. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
10. [Parvovirus B19 infection in patients with congenital blood coagulation disorders].
Aguilar Franco C; Lucía Cuesta JF; Ferrer Torres J; Omeñaca Teres M
Med Clin (Barc); 1997 May; 108(17):641-6. PubMed ID: 9312580
[TBL] [Abstract][Full Text] [Related]
11. Effects of transfusion on human erythrovirus B19-susceptible or -infected pediatric recipients in a genotype 3-endemic area.
Parsyan A; Addo-Yobo E; Owusu-Ofori S; Akpene H; Sarkodie F; Allain JP
Transfusion; 2006 Sep; 46(9):1593-600. PubMed ID: 16965589
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa.
Rubinstein R; Karabus CD; Smuts H; Kolia F; Van Rensburg EJ
Haemophilia; 2000 Mar; 6(2):93-7. PubMed ID: 10781195
[TBL] [Abstract][Full Text] [Related]
13. Seroepidemiology of human parvovirus B19 in Taiwan.
Lin KH; You SL; Chen CJ; Wang CF; Yang CS; Yamazaki S
J Med Virol; 1999 Feb; 57(2):169-73. PubMed ID: 9892403
[TBL] [Abstract][Full Text] [Related]
14. [Investigation of parvovirus B19 seroprevalence in various age groups in Central Anatolia Region, Turkey].
Türk Dağı H; Ozdemir M; Baykan M; Baysal B
Mikrobiyol Bul; 2010 Jul; 44(3):467-72. PubMed ID: 21063997
[TBL] [Abstract][Full Text] [Related]
15. Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood.
Lehmann HW; Knöll A; Küster RM; Modrow S
Arthritis Rheum; 2003 Jun; 48(6):1631-8. PubMed ID: 12794831
[TBL] [Abstract][Full Text] [Related]
16. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G
Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615
[TBL] [Abstract][Full Text] [Related]
17. Incidence and clinical significance of parvovirus B19 infection in patients with rheumatoid arthritis.
Kozireva SV; Zestkova JV; Mikazane HJ; Kadisa AL; Kakurina NA; Lejnieks AA; Danilane IN; Murovska MF
J Rheumatol; 2008 Jul; 35(7):1265-70. PubMed ID: 18484700
[TBL] [Abstract][Full Text] [Related]
18. [Seroprevalence of anti-human parvovirus B19 antibodies in a sample of blood donors in Galicia].
Mata Rebón M; Bartolomé Husson C; Bernárdez Hermida I
Enferm Infecc Microbiol Clin; 1998 Jan; 16(1):25-7. PubMed ID: 9542305
[TBL] [Abstract][Full Text] [Related]
19. Parvovirus B19 transmission by a high-purity factor VIII concentrate.
Wu CG; Mason B; Jong J; Erdman D; McKernan L; Oakley M; Soucie M; Evatt B; Yu MY
Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000
[TBL] [Abstract][Full Text] [Related]
20. Human parvovirus B19 antibodies are less frequent among patients treated with factor IX concentrate inactivated by ultrafiltration: a report from a single Spanish institution.
Canales MA; Pinilla J; Mateos P; Martínez Zapico R; Alvarez T; Jiménez VM; Quintana M; Villar A; Hernández Navarro F; Magallón M
Vox Sang; 1998; 74(4):260-1. PubMed ID: 9691409
[No Abstract] [Full Text] [Related]
[Next] [New Search]
